Pfizer signs up to help manufacture Gilead's scarce coronavirus-fighter remdesivir Insurers saw sky-high profits in Q2. Now Congress wants to take a look at their finances Fauci: Political pressure won’t interfere with FDA decisions on COVID-19 vaccines How Teladoc's blockbuster deal could impact the entire virtual care landscape NIH to fund new diagnostic tests for the emerging, severe childhood illness linked to COVID-19 Healthcare employment cooled off in July, adding 156K jobs Takeda teams up with Novavax to introduce its coronavirus vaccine in Japan AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan Biopharma roundup: So far, so good for Moderna's vaccine trial, Fauci says; Gates Foundation taps Serum Institute to crank out $3 COVID shots Featured Story | By Eric Sagonowsky Pfizer is among the COVID-19 vaccine frontrunners racing to deliver a safe and effective shot, and now it's chipping in with manufacturing on the therapeutic side. The Big Pharma signed on to help produce Gilead's remdesivir, which has been running short at some hard-hit U.S. hospitals. read more |
| |
|---|
|
| | New vaccines will save lives. Who will save the vaccines? The world’s pharmaceutical cold chains do not at this time have the equipment and scale to safely and compliantly deliver a temperature-sensitive COVID-19 vaccine. Click to learn more about emerging trends in vaccine logistics and distribution.
*Republished with permission, this article first appeared on UPS’s thought leadership blog, Longitudes. |
Top Stories By Paige Minemyer We take a look back at health insurers' financial performance, including soaring profits, in Q2. read more By Nick Paul Taylor The FDA has vowed not to let political pressure to approve a COVID-19 vaccine as soon as possible interfere with the regulatory process, Anthony Fauci told Reuters. Fauci’s comments come ahead of an election season in which the availability of a vaccine could influence the vote. read more By Heather Landi Teladoc's move to acquire Livongo is shaking up the health technology market. Here's why analysts and industry leaders think the deal could significantly change the virtual care market and healthcare delivery. read more By Conor Hale While most children exposed to the novel coronavirus suffer only a mild infection, others may develop a rare but severe inflammatory reaction that attacks several organs at once, requiring intensive rescue care. read more By Robert King The healthcare sector added 126,000 jobs in July, a major decline from the 358,000 jobs added in June as the industry continues to battle a financial crisis caused by COVID-19. read more By Angus Liu Takeda has added a vaccine project to its fight against the COVID-19 pandemic. The Japanese pharma, already developing coronavirus treatments, struck a licensing deal to manufacture and market Novavax's vaccine candidate in Japan, aiming for 250 million doses per year. read more By Fraiser Kansteiner Japan called dibs on 120 million doses of AstraZeneca and the University of Oxford's coronavirus vaccine candidate. The British drugmaker aims to import part of that supply, tapping Japan's JCR pharmaceuticals to produce the remaining vaccine substance. Meanwhile, Daiichi Sankyo, Meiji Seika Pharma and KM Biologics will also support supply work in Japan, AZ said. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Moderna's phase 3 enrollment progress won a thumbs up from NIAID chief Anthony Fauci. The Gates Foundation tapped Serum Institute of India to produce low-cost shots. The NIH launched a research effort to create tests for a childhood COVID-19 complication. And researchers are eyeing ACE2 treatments for COVID-19. read more |
